Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PRAN's Cash to Debt is ranked higher than
93% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. PRAN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PRAN' s 10-Year Cash to Debt Range
Min: 16.62  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.91
PRAN's Equity to Asset is ranked higher than
85% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PRAN: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
PRAN' s 10-Year Equity to Asset Range
Min: 0.73  Med: 0.84 Max: 0.99
Current: 0.91
0.73
0.99
F-Score: 3
Z-Score: 7.61
M-Score: -1.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -136.92
PRAN's Operating margin (%) is ranked lower than
58% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. PRAN: -136.92 )
Ranked among companies with meaningful Operating margin (%) only.
PRAN' s 10-Year Operating margin (%) Range
Min: -3850.92  Med: -1606.04 Max: -152.91
Current: -136.92
-3850.92
-152.91
Net-margin (%) -82.02
PRAN's Net-margin (%) is ranked lower than
53% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. PRAN: -82.02 )
Ranked among companies with meaningful Net-margin (%) only.
PRAN' s 10-Year Net-margin (%) Range
Min: -3945.4  Med: -1153.09 Max: -162.37
Current: -82.02
-3945.4
-162.37
ROE (%) -21.24
PRAN's ROE (%) is ranked higher than
57% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. PRAN: -21.24 )
Ranked among companies with meaningful ROE (%) only.
PRAN' s 10-Year ROE (%) Range
Min: -175.24  Med: -79.47 Max: -12.84
Current: -21.24
-175.24
-12.84
ROA (%) -18.84
PRAN's ROA (%) is ranked higher than
57% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. PRAN: -18.84 )
Ranked among companies with meaningful ROA (%) only.
PRAN' s 10-Year ROA (%) Range
Min: -139.67  Med: -54.60 Max: -7.86
Current: -18.84
-139.67
-7.86
ROC (Joel Greenblatt) (%) -175.52
PRAN's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. PRAN: -175.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRAN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21719.66  Med: -7549.23 Max: -546.72
Current: -175.52
-21719.66
-546.72
» PRAN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

PRAN Guru Trades in

PRAN Guru Trades in

Q3 2013

PRAN Guru Trades in Q3 2013

Jim Simons 163,200 sh (New)
» More
Q4 2013

PRAN Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PRAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.31
PRAN's P/B is ranked higher than
77% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. PRAN: 2.31 )
Ranked among companies with meaningful P/B only.
PRAN' s 10-Year P/B Range
Min: 1  Med: 3.42 Max: 31.63
Current: 2.31
1
31.63
P/S 9.00
PRAN's P/S is ranked higher than
60% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. PRAN: 9.00 )
Ranked among companies with meaningful P/S only.
PRAN' s 10-Year P/S Range
Min: 6.75  Med: 20.50 Max: 126.5
Current: 9
6.75
126.5
Current Ratio 10.51
PRAN's Current Ratio is ranked higher than
75% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. PRAN: 10.51 )
Ranked among companies with meaningful Current Ratio only.
PRAN' s 10-Year Current Ratio Range
Min: 4.11  Med: 5.62 Max: 11
Current: 10.51
4.11
11
Quick Ratio 10.51
PRAN's Quick Ratio is ranked higher than
76% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. PRAN: 10.51 )
Ranked among companies with meaningful Quick Ratio only.
PRAN' s 10-Year Quick Ratio Range
Min: 4.11  Med: 5.62 Max: 11
Current: 10.51
4.11
11
Days Sales Outstanding 469.24
PRAN's Days Sales Outstanding is ranked lower than
98% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. PRAN: 469.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRAN' s 10-Year Days Sales Outstanding Range
Min: 0.85  Med: 49.65 Max: 321.2
Current: 469.24
0.85
321.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.98
PRAN's Price/Net Cash is ranked higher than
87% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. PRAN: 1.98 )
Ranked among companies with meaningful Price/Net Cash only.
PRAN' s 10-Year Price/Net Cash Range
Min: 1.03  Med: 7.96 Max: 43
Current: 1.98
1.03
43
Price/Net Current Asset Value 1.60
PRAN's Price/Net Current Asset Value is ranked higher than
91% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. PRAN: 1.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PRAN' s 10-Year Price/Net Current Asset Value Range
Min: 1.03  Med: 7.25 Max: 43
Current: 1.6
1.03
43
Price/Tangible Book 1.85
PRAN's Price/Tangible Book is ranked higher than
82% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. PRAN: 1.85 )
Ranked among companies with meaningful Price/Tangible Book only.
PRAN' s 10-Year Price/Tangible Book Range
Min: 0.63  Med: 6.25 Max: 43
Current: 1.85
0.63
43
Price/Median PS Value 0.10
PRAN's Price/Median PS Value is ranked higher than
91% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. PRAN: 0.10 )
Ranked among companies with meaningful Price/Median PS Value only.
PRAN' s 10-Year Price/Median PS Value Range
Min: 0.54  Med: 0.90 Max: 10.24
Current: 0.1
0.54
10.24
Earnings Yield (Greenblatt) (%) -31.22
PRAN's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. PRAN: -31.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRAN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -31.87  Med: 1407.30 Max: 3142.3
Current: -31.22
-31.87
3142.3

Analyst Estimate

Jun15 Jun16 Jun17
EPS($) -0.03 -0.03 -0.03
EPS without NRI($) -0.03 -0.03 -0.03

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PBT.Australia, PBNA.Germany, PRNAF.USA, PBN.Germany,
Prana Biotechnology Ltd was incorporated on November 11, 1997. The Company is a development stage company at an early stage in the development of its pharmaceutical products. The Company's activities include research into Alzheimer 's disease and other major age-related degenerative disorders.
» More Articles for PRAN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial Jun 30 2015
Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial Jun 30 2015
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease Jun 01 2015
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease Jun 01 2015
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease Jun 01 2015
PBT2 Recommended for Orphan Designation in Europe Apr 27 2015
PBT2 Recommended for Orphan Designation in Europe Apr 27 2015
4 Stocks Under $10 to Trade for Big Breakouts Mar 10 2015
The Worst-Performing Biotech Stocks Of 2014 Jan 01 2015
The Lancet Neurology Publishes Prana's Huntington Disease Trial Nov 19 2014
The Lancet Neurology Publishes Prana's Huntington Disease Trial Nov 19 2014
Horizon Pharma's Actimmune Gets Orphan Drug Designation Oct 07 2014
Prana Biotechnology Up on Orphan Drug Status for PBT2 Sep 08 2014
US STOCKS-S&P 500 ends at record as jobs report eases Fed worries Sep 05 2014
US STOCKS-S&P 500 ends at record as jobs report eases Fed worries Sep 05 2014
US STOCKS-Wall St rises as weak payrolls ease Fed worries Sep 05 2014
US STOCKS-Wall St rises as weak payrolls ease Fed worries Sep 05 2014
US STOCKS-Wall St flat following weak payrolls report Sep 05 2014
US STOCKS-Wall St flat following weak payrolls report Sep 05 2014
Huntington’s Disease Orphan Drug Designation Could Rescue Prana Sep 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK